Continue to Site

Drug Discovery and Development

Nurtec ODT wins approval as a preventive treatment of migraine

By |

Nurtec ODT Biohaven Pharmaceuticals migraine migrainesFDA indicates Biohaven Pharmaceuticals‘ Nurtec ODT for the acute treatment of migraine with or without aura in adults.

The agency recently extended the indication to include the preventive treatment of migraines.

Nurtech is currently the only drug to win FDA approval as both an acute and preventive migraine treatment. The expanded indication has launched the drug into “the next stage of being really disruptive,” according to Biohaven Pharmaceuticals’ CEO Vlad Coric.

Filed Under: Neurological Disease
Tagged With: , , ,
 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected]

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development